Neocleosidos uracil Spiro ocetanoen dated 16 November 2011 is requested by the holder of the invention change the title, now called espironucleosidos uraciclicos oxetanicos

摘要

The invention refers to a formula compound (1), including a possible stereoisomer, that is, R4 is a stereoisomer of phosphate, diphosphate or triphosphate; R4 is a formula (II) or formula (III).R7 IS OPTIONALLY SUBSTITUTED PHENYL, OPTIONALLY SUBSTITUTED PHENYL, OPTIONALLY SUBSTITUTED NAPHTHYL OR OPTIONALLY INDOLILY SUBSTITUTED; R8 AND 48 ARE HYDROGEN, C1-C6ALKIL, BENZIL, OR PHENYL; OR FORM R8 AND R8 C3-C7 CYCLOALIL; IS CL-C10ALKIL, C3-C7CYCLOALKIL, FENILO OR FENILO-C1-C6ALKIL, WHERE THE REST FENILO IN FENILO OR FENILO-C1-C6ALKIL IS OPTIONALLY REPLACED; OR A FAMACEUTICALLY ACCEPTABLE SALT OR SOLVATE; PHARMACEUTICAL FORMULAS AND THE USE OF THE COMPOUNDS I AS HCV INHIBITORS. ON THE DATE OF NOVEMBER 16, 2011, THE SUMMARY OF THE INVENTION IS REQUESTED. "Compounds of formula 1: including any possible stereoisomer thereof,R4 is monophosphate, diphosphate or triphosphate; R4 is or R7 is alternative phenyl, alternative NAFO, or alternative Indian Ocean; R8 and r8'are hydrogeno, C1-C6 pitch, benzene, ofenero; R8 and r8'form cyclo-c3-c7; R9 is c-c10, cyclopropyl compound C3-C7, Phenyl or phenyl 1-c6, in which phenyl or the part of phenyl in phenyl 1-c6 is optional; or an effective and acceptable salt or prescription; a helpful formulation and use of compound 1 as a hexachlorobenzene inhibitor.